Publications by authors named "Sally Clive"

Claim this Profile
F
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.
Gary Middleton, Charlotte Gaskell, Joshua Savage, John Bridgewater, Paul Ross, Sally Clive

J Immunother Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary.
Svenja Harvey, Mark Stares, Julie-Anne Scott, Tharun Joseph Vattam Thottiyil, Alicia-Marie Conway, Sally Clive

Cancer Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis.
Mark Stares, Karin Purshouse, Gillian Knowles, Rachel Haigh, Jenny Irvine, Sally Clive

Br J Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
Philip Pallmann, Fang Wan, Adrian P Mander, Graham M Wheeler, Christina Yap, Sally Clive

Clin Trials· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.
Victoria K Woodcock, Sally Clive, Richard H Wilson, Vicky M Coyle, Michael R L Stratford

Br J Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Embracing model-based designs for dose-finding trials.
Sharon B Love, Sarah Brown, Christopher J Weir, Chris Harbron, Christina Yap, Sally Clive

Br J Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.
Katy J McCann, Ann Mander, Angelica Cazaly, Lindsey Chudley, Jana Stasakova, Sally Clive

Clin Cancer Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors.
Laurence Ridoux, Dorothée R Sémiond, Carine Vincent, Hélène Fontaine, Christine Mauriac, Sally Clive

Anticancer Drugs· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
Marije Slingerland, Dagmar Hess, Sally Clive, Sunil Sharma, Per Sandstrom

Cancer Chemother Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Eric Angevin, Josep Tabernero, Elena Elez, Steven J Cohen, Rastilav Bahleda, Sally Clive

Clin Cancer Res· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
Christopher R Garrett, Tanios S Bekaii-Saab, Theresa Ryan, George A Fisher, Sally Clive

Cancer· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Principles of dose finding studies in cancer: a comparison of trial designs.
Thomas Jaki, Sally Clive, Christopher J Weir

Cancer Chemother Pharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.
Sally Clive, Margaret M Woo, Thomas Nydam, Lindsay Kelly, Margaret Squier

Cancer Chemother Pharmacol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capecitabine (oral 5-fluorouracil pro-drug) treatment for colorectal carcinoma causing ischaemic chest pain.
Trevor Aidan McGoldrick, Duncan Jodrell, Sally Clive

BMJ Case Rep· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of adjuvant treatment in young women with breast cancer.
Sally Clive, J Michael Dixon

Drugs· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis